Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

193.72 +0.50 (+0.26%)
Official Closing Price Updated: 7:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Small-Cap and Value Stocks Poised for Resurgence as Federal Reserve Rate Cuts Loom
The financial markets are on the cusp of a significant "Great Rebalancing," with small-cap and value stocks emerging from a prolonged period of underperformance to challenge the dominance of mega-cap... 
Via MarketMinute
Topics Economy Supply Chain
Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next
Johnson & Johnson investors focus on its pharma strength, legal strategy shift, and growth in medical devices amid sector challenges. 
Via Benzinga
Global Storm Brews: International Headwinds Force Fed's Hand in Pivotal Policy Decisions
The global economy is currently navigating a treacherous landscape, marked by a confluence of significant headwinds that are increasingly dictating the Federal Reserve's monetary policy path.... 
Via MarketMinute
Topics Economy Supply Chain World Trade
P/E Ratio Insights for Johnson & Johnson
 
Via Benzinga
7 No-Brainer Robotics Stocks to Buy Right Now
These robotics leaders are positioned to capitalize as AI transforms machines from tools into intelligent partners. 
Via The Motley Fool
Topics Artificial Intelligence
Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery
The FDA approved Johnson & Johnson's Inlexzo, offering a new bladder cancer treatment option with high response rates for patients, avoiding surgery. 
Via Benzinga
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Global Growth Hits the Brakes: A Mixed Economic Picture Emerges for 2025 and Beyond
The global economy is bracing for a significant slowdown, with leading financial institutions projecting a challenging landscape for 2025 and the years to follow. A confluence of escalating trade... 
Via MarketMinute
Topics Economy Supply Chain World Trade
Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst
Johnson & Johnson analyst Asad Haider says Inlexzo is currently the only intravesical iDRS to deliver cancer meds directly into the bladder. 
Via Benzinga
Navigating the Tempest: An Investor's Guide to the Volatile Bond Market of 2025
The global bond market is braced for continued turbulence in 2025, presenting a complex landscape for investors seeking stability and returns. A confluence of persistent inflation, central bank policy... 
Via MarketMinute
Topics Bonds Economy Retirement
The Federal Reserve Under Siege: A Threat to Monetary Policy Independence
Concerns are escalating over the Federal Reserve's long-standing independence as political pressure intensifies, raising fundamental questions about the future of U.S. monetary policy and its... 
Via MarketMinute
Topics Bonds Economy Government
Yield Curve Steeps Amidst Weakening Labor Market: A Looming Recession or Strategic Pivot for the US Economy?
The United States Treasury yield curve, a bellwether for economic sentiment, has undergone a dramatic transformation around April 2025, shifting from a historically prolonged inversion to a distinct... 
Via MarketMinute
Topics Bonds Economy Workforce
How Do Investors Really Feel About Johnson & Johnson?
 
Via Benzinga
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Investors Brace for Critical CPI Report as Inflation Nears 3% Hurdle
Financial markets are holding their breath as the highly anticipated August 2025 Consumer Price Index (CPI) report looms, a critical barometer for inflation and a potential swing factor for the Federal... 
Via MarketMinute
Topics Bonds Economy World Trade
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
From Johnson & Johnson
Via Business Wire
Will Sticky Services and Tariffs Spoil the Fed's Rate Cut Plans?
Despite widespread market expectations for a September interest rate cut, the Federal Reserve finds itself navigating a perilous economic landscape marked by persistently high inflation. Stubbornly... 
Via MarketMinute
Topics Economy World Trade
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
What does the future hold for Johnson & Johnson? In this episode, we break down the company's strengths, challenges, and what investors can expect moving forward. 
Via The Motley Fool
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
Topics Intellectual Property
Global Equities Brace for a 'September Storm' as Tariffs and Political Turmoil Fuel Volatility
Global equity markets are bracing for a particularly tumultuous September, historically known as a challenging month for investors, now compounded by a fresh wave of geopolitical and domestic policy... 
Via MarketMinute
Topics Bonds Economy Fraud
Navigating the Choppy Waters: Economic Data, Geopolitics, Earnings, and Fed Policy Fuel Market Volatility
The financial markets are currently gripped by a palpable sense of unease, as a perfect storm of economic data, geopolitical events, corporate earnings, and Federal Reserve policy decisions conspire to... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
S&P 500 Soars to Uncharted Territory: Is the Market Overvalued or Justified by a New Era of Growth?
The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Stagflationary Storm Brewing: OECD Warns of Dual Threat to US Economy in Late 2025
The U.S. economy is facing a concerning outlook for late 2025, with the Organisation for Economic Co-operation and Development (OECD) sounding the alarm on a potential "stagflation-lite" scenario. This... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Navigating the 'September Effect': Strategies for Investors in a Historically Volatile Month
As the summer fades and financial professionals return to their desks, the specter of the "September Effect"—a historical tendency for stock markets to deliver their weakest performance of the... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
There is more to like than the dividend with these companies. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Market Jitters: Wall Street Braces for Continued Volatility
The U.S. stock market is once again sending signals of caution, as major indices experienced a notable pullback from their recent record highs in early September 2025. This downturn, following a robust... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Johnson & Johnson Showcases Positive AFib Data, Treatment Results
Johnson & Johnson data shows VARIPULSE safety in AF procedures and Impella CP's long-term survival benefit in cardiogenic shock. 
Via Benzinga
Is Healthcare Setting Up to Be a Quiet Leader Into Year-End?
Over $11 billion flowed into the popular healthcare sector ETF XLV in Q2 alone, suggesting smart money is positioning for a potential rebound. 
Via MarketBeat
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.